Ferron Exports to Poland For A Series of European Market Development

Towards the 50-year journey and dedication of Dexa Group in the pharmaceutical sector, one of the companies in Dexa Group, PT Ferron Par Pharmaceuticals, made its first export to Poland, after exports to United Kingdom in 2008 and Netherlands in 2018. This step made Poland a country after United Kingdom and Netherlands as destinations for export to Europe. The event "The Release of PT Ferron Par Pharmceuticals Prime Exports of Products to Poland" was held at the PT Ferron Par Pharmaceuticals, Cikarang, West Java factory, Tuesday, July 2, 2019.

Dexa Group's commitment to develop the export market has continued to be carried out since the company's first export to Myanmar in 1993. After its first export to Myanmar, Dexa Group continued to explore other export destinations to four continents, namely Africa, America, Asia and Europe.

Avamina SR® products are products that will be exported by Ferron to Poland. Avamina SR® is a product with the same active ingredient as Glucient® SR products that have been exported by Ferron to the United Kingdom and the Netherlands, as well as Glumin XR products which are marketed in Indonesia. In the United Kingdom, Glucient® SR products - which have been exported since 2011 - are in second place for drugs with the active ingredient Metformin Sustained Release. This export proves that Indonesian products have high competitiveness with sustained release technology with competitive prices and quality that meet international standards.

The event "The Release of the Initial Export of PT Ferron Par Pharmceuticals to Poland" was attended by the Minister of Health, Mrs. Prof. Dr. dr. Nila F Moeloek, S.pM (K), Head of the Drug and Food Control Agency (BPOM) Ms. Dr. Ir. Penny K. Lukito, MCP, Minister of Industry Mr. Ir. Airlangga Hartarto MBA MMT and Ambassador of Poland Yang Mulia Beata Stoczyńska, CEO of Dexa Group, Mr. Ferry Soetikno and board of directors of Dexa Group at PT Ferron Par Pharmaceuticals, Cikarang, West Java, Tuesday, July 2, 2019.

"The export of products for Avamina SR® diabetes to Poland is not just our company's milestone. But more than that, this product is a product of the nation's children made at the Cikarang site, as the first pharmaceutical product with sustained release from National pharmaceutical companies, which was successfully exported to Poland. Therefore we are very grateful to the Indonesian POM Agency for providing support and guidance, starting from the development of the SR Metformin formulation to its production with advanced technology, so that this product can provide high added value and can be competitive in highly regulated markets such as the United Kingdom, the Netherlands , and now Poland, "said Managing Director of PT Ferron Par Pharmaceuticals, Mr. Krestijanto Pandji, in the event" The Release of the Initial Export of PT Ferron Par Pharmceuticals Products to Poland "on Tuesday, July 2, 2019.

"We also express our gratitude to the Indonesian Ministry of Health for their suggestions and hopes to realize the independence of the National pharmaceutical companies in producing medicines, so that we can realize that hope. We always support Government programs in providing the best for public health, hopes for all Indonesian people and also the global community. "The spirit of independence in the production of these medicines has enabled us to prove that National pharmaceutical products are able to compete with global pharmaceutical products because of the quality of international standards," he explained.

Through the export of pharmaceutical products for diabetics, said Mr. Krestijanto Pandji, it is hoped that it can provide foreign exchange for the country while strengthening trade economic cooperation between Indonesia and Poland, especially for high-tech products. Poland is one of the highly regulated pharmaceutical products markets, where the country has requirements that are considered very strict and of a high standard for pharmaceutical products.

Avamina SR® products are drugs for diabetics that contain active Sustained Release (SR) Metformin. This technology is designed to simplify the dosage while extending the duration of action of the drug, with a working mechanism that can dissolve slowly along with releasing the drug at a certain period of time until it reaches stable levels in blood plasma. Therefore, consumption of this drug is enough once a day which is consumed together at dinner.

Date Release: 
Wednesday, July 3, 2019 - 10:45